Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study

BackgroundEculizumab, a humanized monoclonal antibody targeting the C5 complement protein, has been approved for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). The aim of this study is to evaluate the long-t...

Full description

Bibliographic Details
Main Authors: Romain Marignier, David Laplaud, Hélène Zéphir, Caroline Papeix, Emmanuelle Leray, Ekbel Amri, Mickaël Piotaix, Jérôme de Sèze
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Neurology
Subjects:
neuromyelitis optica spectrum disorders
eculizumab
real-world evidence
complement inhibition
disease-modifying therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1303874/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1303874/full

Similar Items